Almirall, a CataloniaBio & HealthTech member, and Dermira have started the Phase III study to evaluate the safety and efficacy of lebrikizumab in patients with moderate-to-severe atopic dermatitis.
It is a randomized, double-blind, placebo-controlled clinical trial. The study is expected to enroll a total of 800 adult and adolescent patients at approximately 200 sites in the United States, Europe and Asia.
Topline results from the 16-week induction period expected in the first half of 2021.
In June 2019, Almirall signed with Dermira a license agreement under which Almirall acquired exclusive license rights to develop lebrikizumab for the treatment or prevention of dermatology indications.
Photo: Peter Guenter, CEO of Almirall
Comments